As shown in Table 2, vimentin expression is low or absent in oligodendrogliomas, whereas it is strong and diffuse in glioblastomas and high-grade astrocytomas, highlighting its value in distinguishing tumor aggressiveness. Vimentin serves as a valuable surrogate marker for aggressive glioma phenotypes, particularly DMGs. Here, VIM is linked to central nervous system cancer.